Old Web
English
Sign In
Acemap
>
authorDetail
>
James Lymp
James Lymp
Bristol-Myers Squibb
Medicine
Internal medicine
Outreach
Cancer research
Oncology
8
Papers
99
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
2021
Leukemia & Lymphoma
M. Lia Palomba
Monika Parisi Jun
James Lymp
Andy Nguyen
November McGarvey
Matthew Gitlin
Corey Pelletier
Scott Justin Keating
John Godwin
Show All
Source
Cite
Save
Citations (0)
OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN THE NONUNIVERSITY SETTING
2021
Hematological Oncology
J E Godwin
B. Mattar
Michael B. Maris
C. R. Bachier
Don Stevens
Daanish Hoda
J.C. Varela
Mohamad Cherry
Suzanne R. Fanning
J. Essell
Habte A Yimer
Jay Courtright
Jeffrey P. Sharman
Nikolaus S. Trede
Marina Youssef
James Lymp
P. Shaughnessy
Show All
Source
Cite
Save
Citations (0)
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.
2021
Clinical Pharmacokinectics
Ken Ogasawara
Michael G. Dodds
Timothy Mack
James Lymp
Justine Dell’Aringa
Jeff Smith
Show All
Source
Cite
Save
Citations (1)
Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.
2020
Blood
Jordan Gauthier
Alexandre V. Hirayama
Janaki Purushe
Kevin A. Hay
James Lymp
Daniel H. Li
Cecilia C. S. Yeung
Alyssa Sheih
Barbara S. Pender
Reed M. Hawkins
Aesha Vakil
Tinh-Doan Phi
Rachel N. Steinmetz
Mazyar Shadman
Stanley R. Riddell
David G. Maloney
Cameron J. Turtle
Show All
Source
Cite
Save
Citations (90)
1